HCPCS Code Q5101: Zarxio billing, reimbursement, and modifiers

Key Takeaways

HCPCS Code Q5101 describes injection, filgrastim-sndz (a biosimilar), 1 microgram – the billing code for Zarxio, manufactured by Sandoz

Medicare Part B reimburses Q5101 at ASP+6%; rates are updated quarterly by CMS and must be verified before claim submission

Q5101 is a Q-code (biosimilar), not a J-code; JA and JB identify the route of administration, while JW and JZ report any discarded drug from single-dose containers

Pabau’s claims management software helps oncology and infusion practices track biosimilar drug billing, modifiers, and claim submission in one place

HCPCS Code Q5101 is a Level II code for injection, filgrastim-sndz, a biosimilar, 1 microgram — the code used to bill Zarxio. Most claim denials for this drug trace back to one of three errors: billing J1442 (the reference product) instead of Q5101, omitting the route-of-administration modifier, or submitting with a stale ASP rate after CMS’s quarterly update.

This reference covers the full code descriptor, current Medicare reimbursement methodology, applicable billing modifiers, coverage considerations, and how Q5101 compares to the reference product code J1442. Verify specific payment rates against the current CMS Physician Fee Schedule before submitting claims.

HCPCS Code Q5101: Definition and full code descriptor

HCPCS Code Q5101 is the Level II Healthcare Common Procedure Coding System code for: Injection, filgrastim-sndz, a biosimilar, 1 microgram. The drug it represents is Zarxio, the brand name for filgrastim-sndz manufactured by Sandoz.

Zarxio made history in 2015 as the first FDA-approved biosimilar in the United States, approved under the Biologics Price Competition and Innovation Act (BPCIA). That approval established the Q-code billing pathway that coders still use today. Practices managing infusion services alongside their broader workflows benefit from IV therapy EMR software that supports drug administration documentation alongside claim submission.

Medicare reimbursement for HCPCS Code Q5101 (Zarxio)

Medicare Part B covers Q5101 in outpatient and physician office settings. The payment methodology is ASP+6%: the Average Sales Price of filgrastim-sndz plus a 6% add-on that represents handling and administration overhead.

CMS publishes updated ASP drug pricing files each quarter. Because Q5101 is a biosimilar, its ASP is calculated separately from the reference biologic (Neupogen/J1442), and the two figures are not interchangeable for claim submission purposes. Always verify current rates at the CMS HCPCS coding page before submitting a claim.

Q5101 fee schedule and payment rates

The table below illustrates the ASP-based payment structure for Q5101. Actual dollar figures change quarterly; the rate structure itself is stable. For current verified figures, use the PGM HCPCS lookup tool or download the latest CMS ASP drug pricing file directly.

One practical implication: a practice that switches a patient from Neupogen (J1442) to Zarxio (Q5101) mid-treatment cannot simply substitute the code and expect an identical payment. The ASP figures differ, and the claim must use the code that matches the drug administered on that date of service.

Practices managing multiple biologic and biosimilar products benefit from claims management software that tracks drug-specific billing codes and modifier requirements per encounter.

How to bill HCPCS Code Q5101: Coding and claim submission

Correct Q5101 claim submission requires accurate unit reporting, the right modifier, and a valid diagnosis code establishing medical necessity. Errors in any one of these fields are the leading cause of denials for filgrastim biosimilar billing.

Billing modifiers for Q5101

Route-of-administration modifiers distinguish how the drug was delivered. CMS and many commercial payers require one of these when billing Q5101. Check your MAC’s local policies for current requirements, as modifier rules vary by payer and setting.

The JB modifier is most commonly appended to Q5101 claims because filgrastim-sndz is typically administered subcutaneously in oncology and stem cell mobilization protocols. The JA modifier applies in infusion center or hospital outpatient settings where IV delivery is documented.

Using the wrong modifier, or omitting it when required, results in claim rejection rather than denial — the claim is returned for correction before adjudication begins.

Because Zarxio ships only in single-dose vials and prefilled syringes, JW or JZ must also be appended alongside the route-of-administration modifier. Consistent IV therapy best practices help front-line staff document administration routes and discarded amounts at the point of care, rather than reconstructing them from memory at billing time.

Step-by-step claim submission checklist

1. Confirm the drug administered: Verify the patient received filgrastim-sndz (Zarxio), not the reference biologic Neupogen. Do not substitute Q5101 for J1442 or vice versa.
2. Calculate units accurately: Q5101 is billed per 1 microgram. If the patient received 300 mcg, bill 300 units. Rounding down undercodes; rounding up is a compliance risk.
3. Append the correct modifiers: JB for subcutaneous or JA for IV infusion, plus JW (if any drug was discarded) or JZ (if none was discarded) since Zarxio is supplied only in single-dose containers. Verify your MAC’s current modifier requirements before submission.
4. Attach a supporting ICD-10-CM diagnosis code: Common codes include C91-C96 (leukemias and related hematologic and lymphoid malignancies), Z79.899 (long-term drug therapy), or the specific oncologic indication. The diagnosis must establish medical necessity.
5. Check the current ASP rate: Pull the current quarter’s CMS ASP drug pricing file. Enter the correct expected payment amount in your billing system.
6. Submit on the correct claim form: CMS-1500 for physician office; UB-04 for hospital outpatient. HCPCS Code Q5101 may be billed on either depending on place of service.

Practices that manage oncology drug billing alongside appointment scheduling and documentation often use dedicated EMR built for infusion to keep drug lot numbers, administration routes, and claim details linked to the same patient record.

Simplify biosimilar billing with Pabau

Pabau's claims management software links drug administration documentation to claim submission in one workflow. Track HCPCS codes, modifiers, and ASP-based payment rates without switching between systems.

Book a demo

Coverage policies and payer considerations for Q5101

Medicare Part B covers filgrastim-sndz for FDA-approved indications when medical necessity is established. Coverage criteria, however, vary by Medicare Administrative Contractor (MAC) jurisdiction through Local Coverage Determinations (LCDs). A claim that satisfies Noridian’s LCD may not meet Novitas Solutions’ requirements without additional documentation.

The same MAC-driven variability affects unrelated Part B services, including preventive screening codes such as HCPCS Code G0104.

Three practical coverage rules apply to most Q5101 claims:

• Prior authorization: Most commercial payers require prior authorization for Zarxio. Medicare Part B typically does not, but verify with your specific MAC before assuming coverage is automatic.
• Step therapy: Some commercial payers require documentation that the reference biologic (Neupogen) was considered before approving the biosimilar. Check payer-specific step therapy requirements, particularly for new starts.
• Biosimilar interchangeability by state: Zarxio’s interchangeability status with Neupogen varies by state pharmacy law. In states where substitution is permitted, pharmacists may dispense the biosimilar without a new prescriber authorization. Billing implications depend on what was administered, not what was originally ordered.

Maintaining compliant documentation for every biosimilar administration reduces audit exposure. Practices navigating these requirements can review medspa compliance requirements and HIPAA compliance for practices for broader documentation frameworks that apply across treatment types.

Q5101 documentation requirements for billing

Insufficient documentation is one of the most common reasons Q5101 claims are denied or recouped on audit. Every element below must appear in the medical record before the claim is submitted. Documentation workflows for practices help standardize how this information is captured across a full treatment episode.

• Drug administration record: The exact number of micrograms administered, the date of service, and the administering provider, signed and dated at the time of administration.
• Lot number and NDC: The National Drug Code and lot number from the vial or prefilled syringe label, confirming filgrastim-sndz (Zarxio) rather than the reference biologic or another biosimilar.
• ICD-10-CM diagnosis support: A diagnosis code that matches an FDA-approved indication, with a narrative note establishing medical necessity for the G-CSF administration.
• Route-of-administration documentation: The anatomical site and delivery method, subcutaneous or intravenous, supporting whichever of JA or JB is billed on the claim.
• Discarded-amount documentation: The microgram amount discarded from a single-dose vial or prefilled syringe, or confirmation that none was discarded, supporting the JW or JZ modifier billed.
• ASP verification at time of billing: Confirmation that the expected payment amount matches the current quarter’s CMS ASP drug pricing file, checked before the claim is submitted rather than after a denial.

Structured intake and administration forms remove the reliance on free-text notes, which are harder to audit and easier to leave incomplete. Practices that capture lot numbers, routes, and discarded amounts as structured fields at the point of care spend less time reconstructing documentation after a payer requests it.

Related HCPCS and J-codes for filgrastim

Filgrastim and its biosimilars are billed using a family of related codes. Getting these right prevents miscoding between the reference biologic and its biosimilar alternatives, which is a common audit trigger. The same coding discipline applies across a practice’s full code library, whether that’s CPT Code 11960 or ICD-10 Code M41.9.

Q5101 vs J1442: Biosimilar vs reference product billing

The single most important distinction for coders: Q5101 is the biosimilar code (Zarxio/filgrastim-sndz) and J1442 is the reference product code (Neupogen/filgrastim). They describe chemically similar but not identical drugs, and CMS maintains separate ASP calculations for each.

Q5101 typically carries a lower ASP than J1442, reflecting biosimilar market pricing. Medicare does not require providers to use the biosimilar over the reference product, but some commercial payer formularies and step-therapy protocols do.

The key billing rule: code what was given, not what was ordered or what is cheaper. Miscoding J1442 when Zarxio was administered, or vice versa, is a compliance violation regardless of the payment direction.

Practices can improve accuracy by using prescription management workflows that link the dispensed drug directly to the corresponding billing code at the point of administration.

Clinical context: What is filgrastim-sndz (Zarxio) used for?

Coders who understand the clinical context for Zarxio make fewer documentation errors. Filgrastim-sndz is a recombinant granulocyte colony-stimulating factor (G-CSF) that stimulates production and release of neutrophils from bone marrow. It is used when neutrophil counts drop to clinically dangerous levels.

FDA-approved indications for Zarxio include:

• Chemotherapy-induced neutropenia: Reduces infection risk in patients receiving myelosuppressive cancer treatments
• Acute myeloid leukemia induction or consolidation chemotherapy: Shortens neutrophil recovery time following high-dose regimens
• Bone marrow transplant (BMT) support: Supports neutrophil recovery after autologous and allogeneic transplants
• Peripheral blood progenitor cell (PBPC) collection: Mobilizes stem cells for collection by leukapheresis before transplant
• Severe chronic neutropenia (SCN): Reduces infections in patients with congenital, cyclic, or idiopathic neutropenia
• Acute radiation syndrome (ARS): Increases survival after exposure to myelosuppressive doses of radiation

Each indication maps to a distinct ICD-10-CM diagnosis range. Submitting Q5101 without a diagnosis code that matches one of these approved indications is a common cause of medical necessity denials. Chemotherapy-induced neutropenia in an oncology patient receiving documented myelosuppressive treatment is the highest-volume use case and the one most often audited.

For practices that manage infusion drug administration documentation alongside oncology scheduling, maintaining clean records across the full treatment episode reduces both denial rates and audit exposure. The HIPAA compliance checklist provides a baseline documentation framework applicable across treatment types and settings.

Practices supporting bone marrow transplant and stem cell mobilization protocols alongside Q5101 administration often rely on regenerative medicine EMR software to keep lot numbers, administration routes, and claim details linked to the same patient record.

Conclusion

HCPCS Code Q5101 is a precise billing instrument: every unit corresponds to one microgram administered, the ASP rate changes every quarter, and the modifier tells the payer exactly how the drug was delivered. Getting any one of those three elements wrong invites a denial or, worse, an overpayment audit.

Practices that bill Q5101 regularly benefit most from a workflow that connects drug administration documentation to claim generation without manual rekeying, cutting the transcription errors that make biosimilar billing unpredictable.

To see how this works in practice for infusion and oncology support services, book a demo.

Continue your research

Also billing enteral nutrition supplies? HCPCS Code B4159 covers unit calculation and modifier rules for DME suppliers billing enteral formula.

Coding an anesthesia claim for a vascular procedure? CPT Code 01842 breaks down anesthesia billing for forearm, wrist, and hand embolectomy.

Need a diagnosis code for a musculoskeletal claim? ICD-10 Code M94.1 explains documentation requirements for relapsing polychondritis.

Frequently Asked Questions